title: Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment.
abstract: Resveratrol is known to improve endothelial function in animals, but little is known about its effect on human subjects. Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors underlying endothelial dysfunction. We hypothesized that the modified resveratrol, Longevinex, improves endothelial function in patients with MetS. Thirty-four patients who had been treated for MetS and lifestyle-related disease were randomly assigned to group A, in which Longevinex was administered for 3 months and then discontinued for 3 months, whereas in the time-matched group B, Longevinex was administered between 3 and 6 months. These 2 groups of patients received similar drugs at baseline for diabetes mellitus, dyslipidemia, or hypertension. Flow-mediated dilatation significantly increased during the administration of Longevinex but decreased to baseline 3 months after the discontinuation of Longevinex in the group A patients. Conversely, in the group B patients, flow-mediated dilatation remained unchanged for the first 3 months without Longevinex but was significantly increased 3 months after the treatment with Longevinex. Longevinex did not significantly affect blood pressure, insulin resistance, the lipid profile or inflammatory markers during 6-month follow-up. These results demonstrate that Longevinex specifically improves endothelial function in subjects with MetS who were receiving standard therapy for lifestyle-related disease.
authors: Second Department of Internal Medicine, Kansai Medical University, Moriguchi 570-850, Japan.
authors: Keisuke
authors: K
authors: Fujitaka
authors: Hajime
authors: H
authors: Otani
authors: Fusakazu
authors: F
authors: Jo
authors: Hiromi
authors: H
authors: Jo
authors: Emiko
authors: E
authors: Nomura
authors: Masayoshi
authors: M
authors: Iwasaki
authors: Mitsushige
authors: M
authors: Nishikawa
authors: Toshiji
authors: T
authors: Iwasaka
authors: Dipak K
authors: DK
authors: Das
mesh_terms: D000368:Aged; D003920:Diabetes Mellitus / Q000188:drug therapy; D004339:Drug Compounding; D004730:Endothelium, Vascular / Q000503:physiopathology*; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D007333:Insulin Resistance; D008019:Life Style; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*; D008875:Middle Aged; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage*; D014664:Vasodilation; D014665:Vasodilator Agents / Q000008:administration & dosage*
chemical_list: D013267:Stilbenes; D014665:Vasodilator Agents; D000077185:Resveratrol